EP1206480A2 - Procedes d'obtention de 2-methoxyestradiol tres pur - Google Patents

Procedes d'obtention de 2-methoxyestradiol tres pur

Info

Publication number
EP1206480A2
EP1206480A2 EP00964915A EP00964915A EP1206480A2 EP 1206480 A2 EP1206480 A2 EP 1206480A2 EP 00964915 A EP00964915 A EP 00964915A EP 00964915 A EP00964915 A EP 00964915A EP 1206480 A2 EP1206480 A2 EP 1206480A2
Authority
EP
European Patent Office
Prior art keywords
estradiol
methoxyestradiol
less
estrone
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00964915A
Other languages
German (de)
English (en)
Inventor
Gregory E. Agoston
Anthony M. Treston
Jamshed H. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of EP1206480A2 publication Critical patent/EP1206480A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to the estradiol metabolite 2- methoxyestradiol and to methods of obtaining purified 2- methoxyestradiol.
  • 2-Methoxyestradiol, l,3,5(10)-estratrien-2,3,17 ⁇ -triol-2- methyl-ether (2-ME2) is an endogenous metabolite of estradiol, the major ovarian estrogen.
  • the chemical formula of 2-ME2 is C 19 H 26 0 3 , and the compound has a molecular weight of 302.4.
  • 2-ME2 has low of estrogenic activity but has been found to have other biological effects.
  • U.S. Patent Nos. 5,504,074, 5,661,143, and 5,892,069 to D'Amato et al. disclose methods of treating mammalian diseases characterized by abnormal cell mitosis using 2-ME2.
  • Undesirable cell mitosis is characteristic of many diseases, including, but not limited to, cancer, atherosclerosis, proliferation of solid tumors, vascular malfunctions, endometriosis, retinopathies, arthropathies, and abnormal wound healing.
  • cell mitosis is important in a wide variety of biological functions, including but not limited to the normal development of the embryo, formation of the corpus luteum, cyclic proliferation of uterine endometrium, wound healing, and inflammatory and immune responses.
  • 2-ME2 Any therapeutic use of 2-ME2 in humans requires 2-ME2 having a high level of purity. In general, therapeutic agents are required to be substantially pure to avoid negative side effects of contaminants. In particular, since 2-ME2 has effects that are counteracted by estradiol and other estrogenic metabolites, it is crucial to have a 2-ME2 preparation substantially free of such contaminants. Effects that may be seen from contaminating estradiol, estrone, and 2- hydroxyestradiol include estrogenic effects such as feminization, endometrial proliferation, increased risk of uterine and breast cancer, developmental effects on sexual organs, inhibition of leukopoesis, and effects on hematopoetic cells.
  • 4-hydroxyestradiol, 4-methoxyestradiol, and estradiol are known mutagens and carcinogens. Accordingly, what is needed is a composition of 2-ME2 which is greater than 98% pure and which contains substantially no estradiol or other steroids having estrogenic or carcinogenic effects.
  • composition containing 2-ME2 that is greater than 99.5% pure.
  • the present invention provides 2-ME2 having greater than 98% purity, more preferably greater than 99% purity, most preferably greater than 99.5% purity.
  • the 2-ME2 preparations preferably contain less than 0.03% estradiol, 0.02% or less 2- hydroxyestradiol, 0.02% or less 4-hydroxyestradiol, 0.02% or less 4- methoxyestradiol, and less than 0.02% estrone. More preferably, the 2- ME2 preparations contain 0.01% or less estradiol, 0.02% or less 2- hydroxyestradiol, 0.01% or less 4-hydroxyestradiol, 0.01% or less 4- methoxyestradiol, and 0.01% or less estrone.
  • the present invention also provides methods of obtaining 2-ME2 of greater than 98% purity, more preferably greater than 99% purity, most preferably greater than 99.5% purity.
  • the methods involve synthetic techniques.
  • the methods involve purification techniques to separate the 2-ME2 from other compounds.
  • the methods involve both synthetic techniques and purification techniques described herein.
  • the purification methods involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds.
  • the chromatographic media is preferably silica.
  • the solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
  • an object of the present invention is to provide 2-ME2 having a purity greater than 98%.
  • Another object of the present invention is to provide 2- ME2 substantially free of estradiol, related compounds, and other unwanted impurities.
  • Still another object of the invention is to provide methods of obtaining substantially pure 2-ME2 by synthetic techniques.
  • Another object of the invention is to provide methods of obtaining substantially pure 2-ME2 by purification techniques.
  • Figure 1 is a chromatogram from the reversed phase HPLC analysis of 2-methoxyestradiol available from Sigma Chemical Company (45H4033). This graph shows that the Sigma product contains about 0.034% estradiol.
  • Figure 2 is an expanded view of the chromatogram in Figure 1 indicating the estradiol impurity.
  • Figure 3 is a chromatogram from the reversed phase
  • Figure 4 is an expanded view of the chromatogram in Figure 3 indicating the estrone impurity.
  • Figure 5 is a chromatogram from the reversed phase HPLC analysis of the unpurified 2-methoxyestradiol employed as the starting material in Example 2 of the present invention.
  • Figure 6 is a chromatogram of the 2-ME2 of the present invention produced in Example 2.
  • the HPLC was run with a non- overloaded amount of sample, 75.6 ⁇ g (14 ⁇ l at 5.4 ⁇ l/ml).
  • Figure 7 is an expanded view of the chromatogram in Figure 6.
  • Figure 8 is a chromatogram of the 2-ME2 of the present invention produced in Example 2.
  • the HPLC was run with an overloaded amount of sample, 270 ⁇ g (50 ⁇ l at 5.4 ⁇ l/ml).
  • Figure 9 is an expanded view of the chromatogram in Figure 8.
  • Figure 10 is a chromatogram of the pooled fractions from Example 2, assayed using a gradient (20 to 70% acetonitrile over 25 minutes, 1% acetic acid, and remainder water). 43.2 ⁇ g (8 ⁇ l of the 5.4 ⁇ l/ml sample) was injected.
  • Figure 11 is an expanded view of the chromatogram in
  • Figure 12 depicts a synthetic reaction scheme for the production of the 2-methoxyestradiol of the present invention, using estradiol as a starting material and employing bromine, a crown ether, and a blocking group on the 3- and 17-position hydroxyl oxygen atoms of the estradiol.
  • Figure 13 depicts a synthetic reaction scheme for the production of the 2-methoxyestradiol of the present invention, using estradiol as a starting material and employing bromination at the 2- position of the A ring of unblocked estradiol and a crown ether.
  • Figure 14 depicts a synthetic reaction scheme for the production of the 2-methoxyestradiol of the present invention, using estradiol as a starting material and employing a blocking group on the
  • Figure 15 depicts a synthetic reaction scheme for the production of the 2-methoxyestradiol of the present invention, using estrone as a starting material and employing a blocking group on the 3- position hydroxyl oxygen atom, nitration, and a Sandmeyer reaction.
  • Figure 16 depicts a synthetic reaction scheme for the production of the 2-methoxyestradiol of the present invention, using estradiol as a starting material and employing bromination at the 2- position of the A ring of unblocked estradiol and reaction with methanol.
  • the present invention is directed to 2-methoxyestradiol having a purity of greater than 98.0%, more preferably greater than 99.0%, and most preferably of 99.5% or higher.
  • 2-ME2 can be obtained through synthesis methods or purification methods described herein that yield highly pure 2-ME2. The synthesis methods described herein may also be supplemented with the purification methods described herein to yield 2-ME2 having even greater purity.
  • 2-methoxyestradiol and 2-ME2 are specifically used herein, it should be understood that the methods disclosed herein can be used for synthesis or purification of other compounds, such as, but not limited to, estradiol and other structurally related steroids.
  • the present invention provides methods of synthesizing
  • 2-ME2 to a purity of greater than 98.0%, more preferably greater than 99.0%, and most preferably of 99.5% or higher.
  • the synthetic methods described herein can also be used, with minor modifications, to synthesize other 2- and 4- derivatives or analogues of estradiol, such as, for example, 4-methoxyestradiol and 4-hydroxyestradiol.
  • 2-ME2 can be purified according to the following purification methods to have a purity greater than 98.0%.
  • estradiol as a starting material and utilize a brominated intermediate, as taught by Rao, P.N. et al., Synthesis, 1977, 168 and Chen, S-H et al, Steroids, 1986, 47, 63.
  • the first approach is illustrated in Figure 12.
  • the free hydroxyl groups of estradiol are protected with a blocking group.
  • blocking groups include, but are not limited to, alkyl, aryl, aralkyl groups, and alkyl, aryl, and aralkyl group containing one or more heteroatoms.
  • protection can be accomplished using an alkyl halide, such as benzyl bromide, to form an alkyl ether.
  • alkyl halide such as benzyl bromide
  • Appropriate conditions for hydroxyl protection include reaction of the estradiol and alkyl halide in the presence of NaH and TBAI, optionally in the presence of a solvent, such as dimethyl formamide (DMF).
  • the protected estradiol is then reacted with bromine, for example, in the presence of acetic acid. Protection of the free hydroxyls during bromination gives a higher yield of the 2-brominated intermediate (about 70% vs. about 20% without the protecting groups) (see Cushman, M. et al, J. Med. Chem. 1997, 40, 2323).
  • the bromine is then replaced with a methoxide group using a copper catalyst.
  • a copper catalyst such as Cul.
  • the reaction is preferably conducted in a solvent, such as DMF, optionally in the presence of a promoter.
  • Acceptable promoters include, but are not limited to, crown ethers, such as benzo-15-crown-
  • estradiol or estrone can be used as a starting material in a reaction scheme that utilizes nitro/amine intermediates (see Cushman, M. et al, J. Med. Chem. 1995, 38, 2041). These synthetic approaches are illustrated in Figure 14 (estradiol starting material) and Figure 15 (estrone starting material).
  • the free hydroxyl groups are protected. This protection can be accomplished, for example, using an alkyl halide, such as benzyl bromide, to form an alkyl ether.
  • Appropriate conditions for hydroxyl protection include reaction of the starting material and alkyl halide in the presence of NaH and TBAI, optionally in the presence of a solvent, such as dimethyl formamide (DMF).
  • the protected starting material is then nitrated, for example, with nitric acid and acetic acid or with nitric acid and sulfuric acid, to form the corresponding 2-nitro product.
  • the nitro group is then reduced.
  • Selective reduction can be accomplished by catalytic hydrogenation, for example, hydrogenation in the presence of Pd/C to produce the corresponding 2-amine.
  • the catalytic reduction is optimally carried out for a period of one hour.
  • the 2-amino group can be converted to the 2-methoxy substituent.
  • Catalytic hydrogenation removes the protecting groups to give 2-ME2 when the starting material is estradiol and 2-methoxyestrone when the starting material is estrone. Reduction of the 17-keto group of 2- methoxyestrone with sodium borohydride yields 2-ME2.
  • estradiol as the starting material and utilizes brominated intermediates.
  • the estradiol is ring brominated without first blocking the hydroxyl groups. Bromination is accomplished, for example, with bromine and acetic acid in a solvent, such as THF. This reaction results in bromination at different sites on the ring, including multi- brominated species.
  • the 2-bromo-estradiol can then be isolated from the other brominated intermediates, for example, by chromotography or crystallization, followed by replacement of the bromine with a methoxide.
  • the bromine can be replaced with a methoxide group, for example, using sodium methoxide and methanol in the presence of a copper catalyst, such as Cul, in a manner similar to that described above.
  • a copper catalyst such as Cul
  • the intermediates can be reacted to form the corresponding methoxides, followed by isolation of the 2- methoxyestradiol by the methods described above.
  • the present invention provides methods of purifying 2-
  • the 2-ME2 preparations preferably contain less than 0.03% estradiol, 0.02% or less 2- hydroxyestradiol, 0.02% or less 4-hydroxyestradiol, 0.02% or less 4- methoxyestradiol, and less than 0.02% estrone. Most preferably, the 2-
  • ME2 preparations contain 0.01% or less estradiol, 0.02% or less 2- hydroxyestradiol, 0.01% or less 4-hydroxyestradiol, 0.01% or less 4- methoxyestradiol, and 0.01% or less estrone.
  • the purification methods of the present invention involve liquid chromatography on an adsorption/partition medium such as silica, using a solvent system comprising a polar and a non- polar solvent.
  • the purification methods described herein can also be used, with minor modifications, to purify compounds similar to 2- ME2, such as, for example, 4-methoxyestradiol, 4-hydroxyestradiol, 2- hydroxyestradiol, estradiol, estrone, 2-methoxyestrone, and 4- methoxyestrone.
  • the sample to be purified can be synthesized, or obtained from a biological source.
  • the sample may be a commercially available 2-ME2 preparation, such as those sold by Sigma-Aldrich Chemicals of
  • the sample is preferably at least about 50% pure, more preferably about 75% pure, even more preferably about 90% pure, and most preferably about 98% pure.
  • the sample can be subjected to other purification steps prior to the methods described herein, such as selective crystallization.
  • the sample is preferably dissolved into or solvent- exchanged into a loading solvent, as further described below.
  • the sample is preferably at a concentration in the range of about 0.01 to 2 g/ml, preferably about 0.01 to 1 g/ml, more preferably about 0.05 to 0.2 g/ml.
  • Silica is preferably used as the chromatographic medium. Silica gel of about 70-400 mesh is preferred, most preferably about 70- 230 mesh, such as supplied by Merck and other vendors.
  • the medium can be used loose, in batch chromatography, or packed into a column.
  • Pre-packed columns such as those sold by Biotage of Charlottes ville, VA, can also be used.
  • the medium should be equilibrated in an appropriate solvent before application of the sample to the medium, as further discussed below.
  • the chromatographic methods described herein can be achieved using batch or column chromatography.
  • batch chromatography the sample and the chromatographic medium are combined in a container for a period of time sufficient to allow the 2- ME2 to be retained by the medium.
  • the medium is then preferably washed with wash solvent.
  • Elution solvents are then applied to the medium. After the loading, wash, and elution steps, the solvent is removed from the medium, such as by filtration.
  • a column having appropriate dimensions is packed with the chromatography medium.
  • the column after equilibration with appropriate solvent, is loaded with sample by applying the sample to the top, or entrance, of the column.
  • the ratio of the sample volume to column diameter should preferably be between about 0.2 to 3 ml/ cm, and more preferably between about 0.5 and 1.5 ml/cm for best results.
  • polar solvents such as methanol (MeOH)
  • non-polar solvent such as chloroform (CHC1 3 )
  • Other polar solvents that can be used include, but are not limited to, tetrahydrofuran (THF), ethyl acetate, isopropanol, ethanol, propanol, and combinations thereof.
  • Other non-polar solvents that can be used include, but are not limited to, hexane, dichloromethane, cyclohexane, pentane, and combinations thereof.
  • solvent systems that can be used include THF/hexane, ethyl acetate/hexane, isopropanol/hexane, ethanol/CHCl 3 , propanol /CHC1 3 , isopropanol/CHCl 3 , and combinations thereof.
  • the sample is soluble in the polar solvent. Some amount of the polar solvent, generally about 10%, is needed to render the sample soluble in the loading solvent.
  • the loading solvent thus will include up to about 10% polar solvent and about 90% non-polar solvent.
  • the medium may be washed with a wash solvent that will wash contaminants off the medium but will not elute the 2-ME2.
  • the wash solvent comprises mostly non-polar solvent, with enough polar solvent to prevent the 2-ME2 from precipitating but not enough polar solvent to elute the 2-ME2.
  • the sample is eluted with elution solvent that contains enough polar solvent to elute the 2-ME2 from the medium.
  • the elution solvent may be applied as a step gradient or as a linear gradient, as described below.
  • the wash and elution solvents can be applied to the column in a step gradient or in a linear gradient.
  • the solvents are applied using a step gradient of increasing concentration of polar solvent.
  • the column can be operated using the force of gravity or can be operated with a pump that forces liquids through the column.
  • the rate at which the column is operated will depend upon the volume and dimensions of the column and the silica gel particle size. In general, the column can be operated at a rate from about 0.5 to 5 ml /min.
  • the eluant can be monitored visually or, monitored with a spectrophotometer at a wavelength of about 288 nm, which is the absorbance maximum of 2-ME2, and collected as the 2-ME2 elutes from the column.
  • the column can optionally be operated under pressure and can optionally be heated.
  • Preparative high performance liquid chromatography (HPLC), either normal phase or reversed phase, or fast performance liquid chromatography (FPLC) techniques can be used.
  • HPLC high performance liquid chromatography
  • FPLC fast performance liquid chromatography
  • Commercial preparative chromatography apparatus such as that sold by Biotage of Charlottesville, VA, can also be used. Other known methods of improving column efficiency and/ or speed can also be employed.
  • the eluant can be collected as fractions which are then assayed for 2-ME2 content and purity. These fractions can then be combined to achieve the desired purity of 2-ME2.
  • the fractions can be assayed for purity using reverse phase HPLC with a C-18 column (Waters) and an isocratic solvent system of 30:69:1 acetonitrile:water:acetic acid.
  • Other systems can be used for sample analysis, such those that use solvent gradients instead of the isocratic solvent system; those that use trifluoroacetic acid or formic acid rather than acetic acid; and those that use methanol rather than acetonitrile.
  • the eluant can be monitored in real time and sample collection begun when 2-ME2 of desired purity elutes from the column.
  • the solvent is removed from the pooled fractions by use of a vacuum and/or other solvent removal methods. Lyophilization and other evaporative methods can be used. Preferred Embodiment
  • the medium is silica, which is packed into a column.
  • the sample is dissolved in a mixture of
  • CHC1 3 and MeOH with enough MeOH to solubilize the 2-ME2, generally about 90:10 CHCl 3 :MeOH.
  • the elution conditions are a step gradient from 99:1 CHCl 3 :MeOH to 98:2 CHCl 3 :MeOH.
  • 2-ME2 elutes at about 21.5 minutes, estradiol elutes at about 20.0 minutes, estrone elutes at about 23.2 minutes, 4-hydroxyestradiol elutes at about 15.0 minutes, 4-methoxyestradiol elutes at about 20.4 minutes, 2- hydroxyestradiol elutes at about 15.4 minutes, and 2-methoxyestrone elutes at about 24.4 minutes.
  • Figure 1 Chemicals of St. Louis, Missouri is shown in Figure 1.
  • the sample has an overall purity of 99.2% but has contaminating estradiol of about 0.034%, an unacceptable amount.
  • Figure 2 is an expanded view of the chromatogram of Figure 1.
  • Figure 3 is a chromatogram of a sample obtained from
  • Table 1 illustrates the purity and contaminants of these commercially available samples of 2-ME2 and the purified 2-ME2 of the present invention.
  • a 55 cm diameter (60 cm height) glass column was packed with 600 g silica gel (70-230 mesh from Merck) in 90:10 CHCl 3 :MeOH.
  • the column was washed with one liter of CHC1 3 to remove the MeOH from the column.
  • the sample was 3.5 g 2-ME2 in 60 ml 90:10 CHCl 3 :MeOH.
  • the 2-ME2 was obtained from PharmEco Laboratories, Inc. of Lexington, MA, and was 97.8% pure as determined by analytical HPLC ( Figure 5). The peak eluting at 10.917 is estradiol (2.2%).
  • Analytical HPLC of the starting material, the column fractions, and the pooled product was performed using reverse phase HPLC with a C-18 column (Waters) and an isocratic gradient of 30:69:1 acetonitrile:water:acetic acid, which provides good separation of 2-ME2 and estradiol.
  • the eluant was monitored at a wavelength of 288 nm.
  • the sample was applied to the top of the column and allowed to enter the bed volume.
  • the column was eluted with one liter of 99:1 CHCl 3 :MeOH and then 1.5 L of 98:2 CHCl 3 :MeOH.
  • FIG. 6 Purity of the pooled fractions was determined by analytical HPLC to be 99.984%, using the isocratic technique described above.
  • the HPLC chromatograms are shown in Figures 6 through 9.
  • Figure 6 was generated with a non-overloaded amount of sample, 75.6 ⁇ g (14 ⁇ l at 5.4 ⁇ l/ml).
  • Figure 7 is an expanded view of the chromatogram of Figure 6.
  • the automatic peak finder calculated the 2- ME2 to be 100.0%, although a small, unknown impurity peak is seen in the expanded view, eluted prior to the 2-ME2.
  • Figure 8 was generated with an overloaded amount of sample, 270 ⁇ g (50 ⁇ l at 5.4 ⁇ l/ml).
  • Figure 9 is an expanded view of the chromatogram of Figure 8.
  • the automatic peak finder calculated the 2-ME2 to be 99.984% pure, with a small, unknown, impurity that eluted prior to the 2-ME2, and after estradiol, that was calculated to be 0.016%.
  • the expanded view shown in Figure 9 shows this impurity peak more clearly and shows that the 2-ME2 peak is very clean.
  • the pool was also assayed using a gradient (20 to 70% acetonitrile over 25 minutes, 1% acetic acid, and remainder water).
  • the preparation contained 0.02% or less 2-hydroxy-estradiol, 0.01% or less 4-hydroxy-estradiol, 0.01% or less 4-methoxy-estradiol, and 0.01% or less estrone, as demonstrated by the lack of any measurable peaks at the expected retention times.
  • the purified sample was also subjected to elemental analysis and the results are shown in Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne du 2-méthoxyestradiol d'une pureté supérieure à 98 %, obtenu par des procédés de synthèse ou de purification. Ce 2-méthoxyestradiol très pur, exempt de constituants oestrogéniques, convient particulièrement à une utilisation clinique chez l'homme. Les procédés de purification de l'invention utilisent la chromatographie liquide-solide afin de séparer 2-ME2 des autres composés. Le milieu chromatographique est, de préférence, la silice. Le système solvant comprend un solvant non polaire, tel que le chloroforme, et un solvant polaire, tel que le méthanol.
EP00964915A 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur Withdrawn EP1206480A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15029399P 1999-08-23 1999-08-23
US150293P 1999-08-23
PCT/US2000/023160 WO2001014405A2 (fr) 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur

Publications (1)

Publication Number Publication Date
EP1206480A2 true EP1206480A2 (fr) 2002-05-22

Family

ID=22533881

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00964915A Withdrawn EP1206480A2 (fr) 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur

Country Status (5)

Country Link
EP (1) EP1206480A2 (fr)
JP (3) JP5317381B2 (fr)
AU (1) AU7572600A (fr)
CA (1) CA2376297A1 (fr)
WO (1) WO2001014405A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418876A4 (fr) * 2001-08-17 2007-07-11 Univ Pittsburgh Administration de metabolites de l'oestradiol pour le traitement ou la prevention de l'obesite, du syndrome metabolique, du diabete et de troubles vasculaires et renaux
TW200611909A (en) 2004-08-04 2006-04-16 Akzo Nobel Nv Process for the preparation 2-substituted-derivatives of estrone and estradiol
JP5317690B2 (ja) 2008-12-27 2013-10-16 株式会社東芝 メモリシステム
FR3136464B1 (fr) * 2022-06-13 2026-04-10 Ind Chimica Srl Procédé de purification de 2-méthoxyestradiol de 4-méthoxyestradiol et intermédiaires du procédé
IT202200020784A1 (it) 2022-10-10 2024-04-10 Ind Chimica Srl Processo per la purificazione di 2-metossiestradiolo da 4-metossiestradiolo ed intermedi del processo
IT202200012425A1 (it) 2022-06-13 2023-12-13 Ind Chimica Srl Processo per la purificazione di 2-metossiestradiolo da 4-metossiestradiolo ed intermedio del processo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US6051726A (en) * 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0114405A2 *

Also Published As

Publication number Publication date
CA2376297A1 (fr) 2001-03-01
AU7572600A (en) 2001-03-19
WO2001014405A2 (fr) 2001-03-01
JP2008063345A (ja) 2008-03-21
JP2012211132A (ja) 2012-11-01
JP2003507489A (ja) 2003-02-25
WO2001014405A3 (fr) 2002-01-24
JP5317381B2 (ja) 2013-10-16

Similar Documents

Publication Publication Date Title
US7087592B1 (en) Compositions comprising purified 2-methoxyestradiol and methods of producing same
JP2012211132A (ja) 高純度２−メトキシエストラジオールの生成方法
Potter et al. A convenient, large-scale synthesis of Abiraterone acetate [3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene], a potential new drug for the treatment of prostate cancer
CN114514237B (zh) 用于制备(15α,16α,17β)-雌-1,3,5(10)-三烯-3,15,16,17-四醇(雌四醇)的工艺及所述工艺的中间体
WO2022206870A1 (fr) Procédé de préparation et de purification du composé monométhyl auristatine e
CA2259339C (fr) Cristaux de derives de vitamine d et leur procede de preparation
CA2258681C (fr) Procede de preparation de 17-esters de 9.alpha.,21-dihalo-pregnane-11.beta.,17.alpha.-diol-20-ones
US4145345A (en) Chromatographic purification of maytansine
AU2005211579B8 (en) Compositions comprising purified 2-methoxyestradiol and methods of producing same
AU2007234536B2 (en) Compositions comprising purified 2-methoxyestradiol and methods of producing same
WO2007066158A2 (fr) 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE DE PURETE ELEVEE ET SON PROCEDE DE SYNTHESE
JP2648507B2 (ja) 非極性吸着樹脂の使用下に強心性グリコシドを増量しかつ／または単離する方法
Marrian et al. The partial synthesis of 6-oxo-oestriol and 6α'-hydroxyoestriol
CN111393501A (zh) 牛磺酸-3-脱氢-鹅脱氧胆酸的半缩酮形式结构及牛磺酸-3-脱氢-鹅脱氧胆酸的制法
BG64215B1 (bg) Метод за пречистване на циклоспорин
CN120965785B (zh) L-甘露糖的制备方法
Künzer et al. Regioselective functionalization of 3-oxygenated estra-1, 3, 5 (10)-trienes AT C-1 VIA (η6-arene) Cr (CO) 3 complexes
CA1122590A (fr) Steroides, leur procede de preparation et leur application dans la synthese de steroides marques au tritium
EP4536675B1 (fr) Procédé de purification de 2-méthoxyestradiol à partir de 4-méthoxyestradiol et intermédiaires du procédé
AU733743B2 (en) Sulfatation of estrogen mixtures
CN110741006A (zh) 将粗子囊霉素转化为纯化的吡美莫司的方法
CN120484042A (zh) 一种he3286的合成方法
Villaescusa et al. Steroids and related natural products. 69. Synthesis of 20 (22)-Dihydro-23-deoxodigitoxigenin
CN120309679A (zh) 一种依西美坦的制备方法
CA2166280A1 (fr) Composes de type sterol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020211

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050304